About Kirkstall ltd
Kirkstall Ltd: Revolutionizing Research with Quasi Vivo® Organ-on-a-Chip Technology
Kirkstall Ltd is a leading biotechnology company that specializes in developing innovative solutions for the life sciences industry. The company's flagship product, Quasi Vivo®, is a commercially available organ-on-a-chip technology that has revolutionized the way researchers conduct experiments and tests.
Organ-on-a-chip technology is a relatively new field of research that involves creating miniature versions of human organs on microfluidic chips. These chips are designed to mimic the structure and function of real organs, allowing researchers to study biological processes in a more accurate and realistic way than traditional cell culture methods.
Quasi Vivo® takes this concept one step further by providing an advanced platform for studying complex biological systems. The technology consists of microfluidic chambers that can be customized to simulate different organs or tissues, such as liver, lung, kidney or gut. Each chamber contains living cells that are cultured under controlled conditions to create an environment similar to what would be found in the body.
The benefits of using Quasi Vivo® are numerous. Firstly, it provides more human-relevant data than traditional cell culture methods because it closely mimics the physiological conditions found in vivo (in living organisms). This means that researchers can obtain more accurate results when testing drugs or other compounds for safety and efficacy.
Secondly, Quasi Vivo® allows researchers to study multiple organs simultaneously on a single chip. This means they can investigate how different organs interact with each other and how diseases affect multiple systems at once - something which is impossible with traditional methods.
Thirdly, Quasi Vivo® reduces animal testing by providing an alternative method for preclinical studies. By using organ-on-a-chip models instead of animals, researchers can reduce costs and ethical concerns associated with animal experimentation while still obtaining reliable data.
Kirkstall Ltd offers a range of products based on its Quasi Vivo® technology, including pre-made chips for specific organs and custom-designed chips for more complex experiments. The company also provides training and support to help researchers get the most out of their Quasi Vivo® systems.
Applications of Quasi Vivo® are wide-ranging, from drug discovery and toxicology testing to disease modeling and personalized medicine. The technology has already been used in a variety of research areas, including cancer, infectious diseases, neurodegenerative disorders, and more.
In conclusion, Kirkstall Ltd is at the forefront of organ-on-a-chip technology with its innovative Quasi Vivo® platform. By providing a more human-relevant approach to research, the company is helping to advance our understanding of complex biological systems and improve drug development processes. With its range of products and applications, Kirkstall Ltd is poised to make a significant impact on the life sciences industry in the years ahead.
kirkstall.org
